ANCA-associated vasculitis research hub
5 indexed studies · 1 currently recruiting
- completedPhase II
Obinutuzumab compared with rituximab for treating ANCA-associated vasculitis
This UK study compares two medicines for ANCA-associated vasculitis: the standard treatment, rituximab, and a newer drug, obinutuzumab. Both drugs work by clearing immune cells that cause blood vessel inflammation. Researchers want to see if obinutuzumab clears these cells more effectively and helps prevent future flare-ups over 18 months.
United Kingdom - recruitingNA
Biocollection of Patients With ANCA Associated Vasculitis
This study is collecting samples like blood and urine from people with a rare condition called ANCA-associated vasculitis. Researchers want to understand the disease better, predict future health issues, and find personalised ways to manage it, ultimately improving lives and treatments.
France - active not recruitingPHASE2
ETA and AT1 Antagonism in ANCA-vasculitis (SPARVASC)
This study looks at a new drug, sparsentan, for people with ANCA-associated vasculitis. It aims to see if blocking certain chemicals can help improve blood vessel health, which is important for preventing heart attacks and strokes in these patients.
United Kingdom - active not recruiting
Avacostar - (PASS)
This study looks at people with a serious condition called ANCA-associated vasculitis (AAV). It compares a new medicine, avacopan, with standard treatments to see how people get on and if there are any specific health events. It's not a trial where you get a new treatment, but observes real-world care.
Germany · United Kingdom - active not recruiting
Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated Vasculitis
This study looks at how a common virus (CMV) affects people with a rare condition called ANCA-associated vasculitis (AAV), especially when they first get sick or have a flare-up. We want to see if CMV reactivation makes the condition worse.
United Kingdom